Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria

Stefano Porzio, Paola Bossù, Paolo Ruggiero, Diana Boraschi, Aldo Tagliabue

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Mucosal delivery of therapeutic protein drugs or vaccines is actively investigated, in order to improve bioavailability and avoid side effects associated with systemic administration. Orally administered bacteria, engineered to produce anti-inflammatory cytokines (IL-10, IL-1Ra), have shown localised ameliorating effects in inflammatory gastro-intestinal conditions. However, the possible systemic effects of mucosally delivered recombinant bacteria have not been investigated. Results: B. subtilis was engineered to produce the mature human IL-1 receptor antagonist (IL-1Ra). When recombinant B. subtilis was instilled in the distal colon of rats or rabbits, human IL-1Ra was found both in the intestinal lavage and in the serum of treated animals. The IL-1Ra protein in serum was intact and biologically active. IL-1-induced fever, neutrophilia, hypoglycemia and hypoferremia were inhibited in a dose-dependent fashion by intra-colon administration of IL-1Ra-producing B. subtilis. In the mouse, intra-peritoneal treatment with recombinant B. subtilis could inhibit endotoxin-induced shock and death. Instillation in the rabbit colon of another recombinant B. subtilis strain, which releases bioactive human recombinant IL-1β upon autolysis, could induce fever and eventually death, similarly to parenteral administration of high doses of IL-1β. Conclusions: A novel system of controlled release of pharmacologically active proteins is described, which exploits bacterial autolysis in a non-permissive environment. Mucosal administration of recombinant B. subtilis causes the release of cytoplasmic recombinant proteins, which can then be found in serum and exert their biological activity in vivo systemically.

Original languageEnglish
Article number27
JournalBMC Biotechnology
Volume4
DOIs
Publication statusPublished - Oct 30 2004

Fingerprint

Interleukin-1 Receptors
Anti-Inflammatory Agents
Bacteria
Interleukin-1
Autolysis
Colon
Mucosal Administration
Fever
Rabbits
Therapeutic Irrigation
Serum
Hypoglycemia
Recombinant Proteins
Endotoxins
Interleukin-10
Biological Availability
Blood Proteins
Shock
Proteins
Vaccines

ASJC Scopus subject areas

  • Medicine(all)
  • Biotechnology

Cite this

Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. / Porzio, Stefano; Bossù, Paola; Ruggiero, Paolo; Boraschi, Diana; Tagliabue, Aldo.

In: BMC Biotechnology, Vol. 4, 27, 30.10.2004.

Research output: Contribution to journalArticle

Porzio, Stefano ; Bossù, Paola ; Ruggiero, Paolo ; Boraschi, Diana ; Tagliabue, Aldo. / Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. In: BMC Biotechnology. 2004 ; Vol. 4.
@article{135b0a874e244203a6a5afddf37fb42e,
title = "Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria",
abstract = "Background: Mucosal delivery of therapeutic protein drugs or vaccines is actively investigated, in order to improve bioavailability and avoid side effects associated with systemic administration. Orally administered bacteria, engineered to produce anti-inflammatory cytokines (IL-10, IL-1Ra), have shown localised ameliorating effects in inflammatory gastro-intestinal conditions. However, the possible systemic effects of mucosally delivered recombinant bacteria have not been investigated. Results: B. subtilis was engineered to produce the mature human IL-1 receptor antagonist (IL-1Ra). When recombinant B. subtilis was instilled in the distal colon of rats or rabbits, human IL-1Ra was found both in the intestinal lavage and in the serum of treated animals. The IL-1Ra protein in serum was intact and biologically active. IL-1-induced fever, neutrophilia, hypoglycemia and hypoferremia were inhibited in a dose-dependent fashion by intra-colon administration of IL-1Ra-producing B. subtilis. In the mouse, intra-peritoneal treatment with recombinant B. subtilis could inhibit endotoxin-induced shock and death. Instillation in the rabbit colon of another recombinant B. subtilis strain, which releases bioactive human recombinant IL-1β upon autolysis, could induce fever and eventually death, similarly to parenteral administration of high doses of IL-1β. Conclusions: A novel system of controlled release of pharmacologically active proteins is described, which exploits bacterial autolysis in a non-permissive environment. Mucosal administration of recombinant B. subtilis causes the release of cytoplasmic recombinant proteins, which can then be found in serum and exert their biological activity in vivo systemically.",
author = "Stefano Porzio and Paola Boss{\`u} and Paolo Ruggiero and Diana Boraschi and Aldo Tagliabue",
year = "2004",
month = "10",
day = "30",
doi = "10.1186/1472-6750-4-27",
language = "English",
volume = "4",
journal = "BMC Biotechnology",
issn = "1472-6750",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria

AU - Porzio, Stefano

AU - Bossù, Paola

AU - Ruggiero, Paolo

AU - Boraschi, Diana

AU - Tagliabue, Aldo

PY - 2004/10/30

Y1 - 2004/10/30

N2 - Background: Mucosal delivery of therapeutic protein drugs or vaccines is actively investigated, in order to improve bioavailability and avoid side effects associated with systemic administration. Orally administered bacteria, engineered to produce anti-inflammatory cytokines (IL-10, IL-1Ra), have shown localised ameliorating effects in inflammatory gastro-intestinal conditions. However, the possible systemic effects of mucosally delivered recombinant bacteria have not been investigated. Results: B. subtilis was engineered to produce the mature human IL-1 receptor antagonist (IL-1Ra). When recombinant B. subtilis was instilled in the distal colon of rats or rabbits, human IL-1Ra was found both in the intestinal lavage and in the serum of treated animals. The IL-1Ra protein in serum was intact and biologically active. IL-1-induced fever, neutrophilia, hypoglycemia and hypoferremia were inhibited in a dose-dependent fashion by intra-colon administration of IL-1Ra-producing B. subtilis. In the mouse, intra-peritoneal treatment with recombinant B. subtilis could inhibit endotoxin-induced shock and death. Instillation in the rabbit colon of another recombinant B. subtilis strain, which releases bioactive human recombinant IL-1β upon autolysis, could induce fever and eventually death, similarly to parenteral administration of high doses of IL-1β. Conclusions: A novel system of controlled release of pharmacologically active proteins is described, which exploits bacterial autolysis in a non-permissive environment. Mucosal administration of recombinant B. subtilis causes the release of cytoplasmic recombinant proteins, which can then be found in serum and exert their biological activity in vivo systemically.

AB - Background: Mucosal delivery of therapeutic protein drugs or vaccines is actively investigated, in order to improve bioavailability and avoid side effects associated with systemic administration. Orally administered bacteria, engineered to produce anti-inflammatory cytokines (IL-10, IL-1Ra), have shown localised ameliorating effects in inflammatory gastro-intestinal conditions. However, the possible systemic effects of mucosally delivered recombinant bacteria have not been investigated. Results: B. subtilis was engineered to produce the mature human IL-1 receptor antagonist (IL-1Ra). When recombinant B. subtilis was instilled in the distal colon of rats or rabbits, human IL-1Ra was found both in the intestinal lavage and in the serum of treated animals. The IL-1Ra protein in serum was intact and biologically active. IL-1-induced fever, neutrophilia, hypoglycemia and hypoferremia were inhibited in a dose-dependent fashion by intra-colon administration of IL-1Ra-producing B. subtilis. In the mouse, intra-peritoneal treatment with recombinant B. subtilis could inhibit endotoxin-induced shock and death. Instillation in the rabbit colon of another recombinant B. subtilis strain, which releases bioactive human recombinant IL-1β upon autolysis, could induce fever and eventually death, similarly to parenteral administration of high doses of IL-1β. Conclusions: A novel system of controlled release of pharmacologically active proteins is described, which exploits bacterial autolysis in a non-permissive environment. Mucosal administration of recombinant B. subtilis causes the release of cytoplasmic recombinant proteins, which can then be found in serum and exert their biological activity in vivo systemically.

UR - http://www.scopus.com/inward/record.url?scp=13244252314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244252314&partnerID=8YFLogxK

U2 - 10.1186/1472-6750-4-27

DO - 10.1186/1472-6750-4-27

M3 - Article

C2 - 15516267

AN - SCOPUS:13244252314

VL - 4

JO - BMC Biotechnology

JF - BMC Biotechnology

SN - 1472-6750

M1 - 27

ER -